Aditeren, a dihydrofolate reductase inhibitor, possesses bactericide and diuretic activities. This compound has never been marketed.

Fenquizone is the diuretic drug. The distribution of fenquizone labelled with 14C in mice was studied by means of an autoradiographic technique. High concentration of radioactivity was found in the intestine, liver, kidney, blood, myocardium and skeletal muscles in decreasing order at various times after oral administration. The labelled compound did not cross the blood-brain barrier. Fenquizone is a saluretic with a quinazolone structure which acts by blocking reabsorption of sodium in the proximal tubule and the ascending branch of the loop of Henle, as well as in the proximal section of the convoluted distal tubule. At low doses fenquizone has an hypotensive action without showing the characteristics secondary effects of diuretics so that it can be employed for long-term treatments without any risk. Fenquizone showed also a significant decrease of symptoms (headache, dizziness) due to hypertension. No undesirable side effects were observed.

Canrenone, a spironolactone metabolite, is a mineralocorticoid receptor antagonist. Canrenone is used as a diuretic in Europe and, in particular, in Italy under brand name Luvion. Luvion is a tablet for oral application which is effective for the treatment Hyperaldosteronism primary, secondary hyperaldosteronism from edematous states ( heart failure congestive, cirrhosis of the liver in phase ascites, nephrotic syndrome) and arterial hypertension essential where other therapies were not sufficiently effective or tolerate. In addition was suggested that canrenone might represent an effective therapy for idiopathic post-puberal hirsutism and it normalizds the cardiac response to the postural challenge in patients with preascitic cirrhosis. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.

Epithiazide (epithizide) is a diuretic drug. Its combination with Veriloid under the trade name Thiaver was used in the 1960s for the treatment of hypertension.

Penflutizide ‎is a thiazide diuretic drug, Na+-Cl- symport inhibitor. Penflutizide was shown to have high potency to photooxidize lipids. Penflutizide -photosensitized peroxidation of squalene was repressed by the presence of sodium azide or 2,5-dimethylfuran and was accelerated in a D2O suspension. These findings suggest the participation of singlet oxygen in Penflutizide photoperoxidation of squalene (type II mechanism). Penflutizide -photosensitized lysis of red blood cells (RBC) accompanied by formation of hydroperoxides in RBC membrane lipids was also noted. These results suggested that membrane lipids can be one of the target molecules of Penflutizide phototoxicity. Penflutizide ‎is an ingredient of the drug Praemenstron manufactured by Nordmark Arzneimittel and consisting of Flumedroxone, Meprobamate, Penflutizide.

Mebutizide is a medium strength antihypertensive diuretic (similar to hydrochlorothiazide and altizide).

Etozolin is a diuretic used in Europe under the names Diulozin, Elkapin, Etopinil for the treatment of edema and hypertension. The exact mechanism of etozolin action is unknown. The current marketing status of the drug is unavailable and is supposed to be discontinued.

Paraflutizide is a thiazide diuretic, which is used in the treatment of hypertension.

Cyclopenthiazide is a thiazide diuretic. It inhibits the Na+-Cl− symporter in the distal convoluted tubule of the kidney. Cyclopenthiazide is used for the treatment of edema, including that associated with heart failure, and for the treatment of hypertension.

Clorexolone is a diuretic developed by May & Baker for the treatment of hypertension. The drug was marketed under the name Nefrolan, however its current status is unknown and supposed to be discontinued, at least in Europe.